These posters highlight key data supporting the rationale for the Phase 1b program in biomarker-selected cancers as a single agent, and in combination with market leading therapies to overcome ...

Sonoma Biotherapeutics Announces Oral and Poster Presentations at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting Sonoma Biotherapeutics, Inc., a clinical-stage ...

BETHESDA, Md., April 30, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation ...

When is the oral poster presentation scheduled? The oral poster presentation is scheduled for Saturday, May 10, 2025, from 8:00-9:00 a.m. EST. What is the role of GT-02287 in treating Parkinson ...

Phase 1a dose-escalation study data update: treatment with NXP900 resulted in exposure levels leading to robust pharmacodynamic responses across a range of tolerated doses; NXP900 has an acceptable ...

These posters highlight key data supporting the ... “This year’s AACR presentations mark an important milestone in the development of NXP900. As new preclinical data continue to unlock the ...